Search

Press release: Breaking news on lymph node cancer and plasma cell cancer reported at Hematology Congress in Stockholm, June 13-16, 2013

Jun 10 2013 Posted in Press releases

In order to support high-quality science, the European Hematology Association (EHA) collaborates with 16 Scientific Working Groups (SWGs) and concentrates on fostering activities directed towards basic and translational research.

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

Dec 13 2023

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

Jun 14 2013

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Exciting developments in Lymphoma (lymphnode cancer) and Myeloma (plasma cell cancer) to be presented at European Hematology Congress in Stockholm, June 13-16, 2013

Mar 27 2013 Posted in Press releases

Myeloma, until recently a fatal bone marrow malignancy with a short survival time, is now turning into a chronic disease.